Related Experiment Video
Updated: Aug 9, 2025

06:08
A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
23.5K
[Noninvasive stratification of primary aldosteronism: a glimpse of latest updates]
1Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Zhonghua Nei Ke Za Zhi
|February 23, 2023
Abstract
No abstract available in PubMed .
Related Concept Videos
Hypertension III: Clinical Manifestations and Diagnostic Studies
36
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
36
Acute Coronary Syndrome III: Diagnostic Studies
19
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
19
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
479
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
479

